Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months Canada NewsWire VICTORIA, BC, Nov. 20, 2024...
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting Canada NewsWire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /CNW/ - Eupraxia...
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis Canada NewsWire VICTORIA, BC, Nov. 12, 2024...
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.39 | -8.14196242171 | 4.79 | 4.89 | 4.13 | 13500 | 4.61267252 | CS |
4 | 0.05 | 1.14942528736 | 4.35 | 5.45 | 3.89 | 28066 | 4.60491548 | CS |
12 | 0.99 | 29.0322580645 | 3.41 | 5.45 | 3.07 | 31971 | 4.12985925 | CS |
26 | 0.71 | 19.2411924119 | 3.69 | 5.45 | 3.07 | 23459 | 3.92079193 | CS |
52 | -1.42 | -24.3986254296 | 5.82 | 7.64 | 3.07 | 33049 | 4.34848298 | CS |
156 | 2.4 | 120 | 2 | 9.1 | 0.8 | 27709 | 4.25210602 | CS |
260 | -3.35 | -43.2258064516 | 7.75 | 9.1 | 0.8 | 25165 | 4.22878532 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.